- Health Needs for Bi Men
- Prostate Cancer Registry Helps Black Men
- Quick Start to Healthy Weight Loss
- ‘Really, Really Messed Up My Life’
- Black Men Can Beat Prostate Cancer
- Health Screenings for Older Black Men
- Healthy Man of the Month for July 2016
- HIV Testing is HIV Prevention
- Your ‘Mental’ Endurance
- Entertainment CEO DonJuan Clark
Better Cancer Treatments Coming
A new tool could help doctors treat cancer patients by choosing the most effective combination of drugs by considering the genetic sensitivities of a tumor and the “spillover” benefits of drugs for a specific patient’s cancer. This is great progress for cancer patients that could lengthen lives.
Tyrosine kinase inhibitors block proteins that help mutated genes in cancerous cells. The drugs often affect other proteins, which is called “drug spillover.”
Using the Genomics of Drug Sensitivity in Cancer database, the Kinase Addiction Ranker is shown in a study published in Bioinformatics to predict the genetic motivators powering cells in a tumor and select a kinase inhibitor to block them.
“A lot of these kinase inhibitors inhibit a lot more than what they’re supposed to inhibit. Maybe drug A was designed to inhibit kinase B, but it also inhibits kinase C and D as well. Our approach centers on exploiting the promiscuity of these drugs, the ‘drug spillover’,” said Dr. Aik Choon Tan, an associate professor of Bioinformatics at the University of Colorado School of Medicine, in a press release.
In the study, researchers worked with 151 leukemia patients and 21 cancer cell lines, the information for which were fed into the KAR. The tool ranks the kinases most important to the growth of the cancer and then offers combinations of existing drugs that would be most effective at blocking those kinases.
The suggestions from the tool were shown to predict the correct outcomes from the leukemia patients’ treatment, and its suggestions for the cancer cell lines matched the results of experiments in the lab.
Article courtesy of United Press International.